Physician profile
Alan Wayne Hurty
NPI 1225020191
$2,148.25
in general payments reported to CMS, 2019-2025
24 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $468 · 2021: $140 · 2022: $153 · 2023: $500 · 2024: $61.83 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768 · Education: $95.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.77 |
| Education | $95.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $754.16 | 2019-2025 | Farxiga, Brilinta, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.16 | 2019-2021 | |
| Edwards Lifesciences Corporation | $154.19 | 2023 | |
| Novartis Pharmaceuticals Corporation | $135.76 | 2019-2022 | |
| Philips North America LLC | $111.24 | 2023-2025 | (Ck4) Mcot, Mcot |
| Janssen Pharmaceuticals, INC | $105.40 | 2019-2021 | |
| Argenx US, INC. | $76.76 | 2025 | Vyvgart Hytrulo |
| Biotronik INC. | $68.54 | 2023 | Acticor 7 Vr-T Dx |
| Pfizer INC. | $68.09 | 2019 | |
| Baxter Healthcare | $57.64 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Lilly USA, LLC | $42.50 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.65 | 2025 | |
| Amarin Pharma, INC. | $37.38 | 2020 | |
| Medicomp INC | $30.46 | 2023 | Telepatch Cardiac Monitor |
| Actelion Pharmaceuticals US, INC. | $24.23 | 2023 | Uptravi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.21 | 2025 | |
| Amgen INC. | $21.76 | 2020 | |
| Boston Scientific Corporation | $19.71 | 2020 | |
| Gilead Sciences, INC. | $19.37 | 2019 | |
| Organogenesis INC. | $18.52 | 2023 | Puraply |
| Xeris Pharmaceuticals, INC. | $17.56 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.60 | 2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $14.75 | 2019 | |
| Tactile Systems Technology INC | $14.61 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Hurty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.